Osteoimmunological insight in to vertebral fractures in osteoporosis

Iranian Journal of Public Health

Volumn 37, Issue , 2008, Pages 7-15

  Saghafi, Hamid ^a   Hossein Nezhad, Arash ^a   Sedighi, Nahid ^b   Tofighi, P ^a   Soltani, A ^a   Larijani, Bagher ^a   Hafezi, Rahmatollah ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone turnover; Osteoimmunology; Osteoprotegerin; RANKL; Vertebral fractures

Indexed keywords

EID: 75449088489     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Melton LJ, Chrischilles EA, Lane AW, Riggs BL (1992). How many women have os-teoporosis? JBMR, 7: 1005–10.
2. Aaron J, Choi Y (2000). Bone versus im-mune system. Nature, 408: 535-36.
3. Gowen M, Wood DD, Ihirie EJ, Mcguir MKB, Russell RGG (1983). An inter-leukin-1 like factor stimulates bone re-sorption in vitro. Nature, 306: 378-80.
4. Gowen M, Wood DD, Russell RGG (1985). Stimulation of the proliferation of human bone cells in vitro by human mono-cyte products with IL-1 activity. JCI, 75: 1223-29.
5. Garrett IR, Durie BGM. Nedwin GE, et al. (1987). Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. NEJM, 317: 526-32.
6. Tashjian AH, Voelkel EF, Lazzaro M, Goad D, Bosma T, Levine L (1987). Tumour necrosis factor-a (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin mediated mechanism. En-docrinol, 120: 2029-36.
7. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986). Stimula-tion of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature, 319: 516-18.
8. Pacifici R, Rifas L, Teitelbaum S, et al. (1987). Spontaneous release of inter-leukin-1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. PNAS, 84: 4616-20.
9. Pacifici R, Brown C, Puscheck E, et al. (1991). The effect of surgical menopause and estrogen replacement on cytokine release from human blood monocytes. PNAS, 88: 5134-38.
10. Lorenzo J (1998). Mice lacking the type 1 Interleukin-1 receptor do not lose bone mass after ovariectomy. Endocrinol, 139: 3022-25.
11. Ammann P, Garcia I, Rizzoli R, Meyer JM, Vassalli P (1997). Transgenic mice ex-pressing high levels of soluble tumour necrosis factor receptor-1 fusion protein are protected from bone loss caused by oestrogen deficiency. JCI, 99(7): 1699-1703.
12. Chaudhary L, Spelsberg TC, Riggs BL (1992). Production of various cytokines by normal human osteoblast-like cells in re-sponse to interleukin-1b and tumour necrosis factor-a: lack of regulation by 17b-estradiol. Endocrinol, 130: 2528–34.
13. Birch MA, Ginty AF, Walsh CA, Fraser WD, Gallagher J, et al. (1993). PCR de-tection of cytokines in normal human and pagetic osteoblast-like cells. JBMR, 8: 1155-62.
14. Girasole G, Jilka RL, Passeri BS, Boder G, Williams DC, Manolagas S (1992). 17b Estradiol inhibits IL-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the anti osteoporotic effects of estrogens. JCI, 89: 883-91.
15. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999). Modu-lation of osteoclast differentiation and function by the new members of the tu-mor necrosis factor receptor and ligand families. Endocr Rev, 20: 345-57.
16. Rodan GA, Martin TJ (1982). Role of os-teoblasts in hormonal control of bone resorption a hypothesis [letter]. Calcif. Tissue Int, 34: 349-51.
17. Raisz LG (2005). Pathogenesis of osteopo-rosis: concepts, conflicts, and prospects. JCI, 115: 3318-25.
18. Rauner M, Sipos W, Pietschmann P (2007). Osteoimmunology. Int Arch Allergy Im-munol, 143: 31-48
19. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL (2003). Role of RANK ligand in mediating increased bone resorption in early post-menopausal women. J Clin Invest, 111: 1221-30.
20. Abdallah BM, Stilgren LS, Nissen N, Kassem M, Jorgensen HR, Abrahamsen B (2005). Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int, 76: 90–97.
21. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y (1999). Immunological characterization of circulation osteoprotegerin/ osteoclastogenesis in inhibitory factor: increased serum concentrations in post-menopausal women with osteoprosis. JBMR, 14: 518-27.
22. Riggs BL, Khosla S, Atkinson EJ, Dunstan CR, Melton LJ (2003). Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen defi-ciency. Osteoporos Int, 14: 728-33.
23. Grigrie D, Neacsu E, Marinescu M, Popa O (2003). Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. Rom J Intern Med, 41: 409-15.
24. Mezquita-Raya P, de la Higuera M, Garcia DF, Alonso G, Ruiz-Requena ME, de Dios Luna J, Escobar-Jimenez F, Monoz-Tprres M (2005). The contribution of serum osteoprotegerin to bone mass and ver-tebral fractures in postmenopausal women. Osteoporos Int, 16: 1368–74.
25. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, Bonelli C, Dimai HP, Leb G, Obermayer-Pietsch B (2003). Osteo-protegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Woch-enschr, 115: 291-97.
26. Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Zh, Sun LH, Xu MY, Chen JL (2005). Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int, 76: 1-6.
27. Schett G, Kiechl S, Redlich K, Oberhollen-zer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J (2004). Soluble RANKL and risk of nontraumatic fracture. JAMA, 291: 1108-13.
28. Banks LM, van Juijk C, Genant HK (1995). Radiographic technique for assessing os-teoporotic vertebral fracture. In: Vertebral Fracture in Osteoporosis. Eds, Ra-diology Research and Education Founda-tion. San Francisco, California, USA, pp. 131-47
29. World Health Organization (1994). Assessment of fracture risk and its application to screening for postmenopausal osteo-porosis. WHO Technical Report Series, 843: 1-24.
30. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993). Vertebral fracture assessment us-ing a semiquantitative technique. JBMR, 8: 1137-48.
31. Larijani B, Hossein-Nezhad A, Mojtahedi A, Pajouhi M, Bastanhagh MH, Soltani A, Mirfezi SZ, Dashti R (2005). Norma-tive data of Bone Mineral Density in healthy population of Tehran, Iran: A Cross sectional study. BMC Musculoskelel Disord, 6: 38.
32. Tofighi P, Hossein-Nezhad A, Sedighi N, et al. (2007). Vertebral geometry parame-ters can predict fractures. Iranian J Publ Health Supplementary issue of osteo-porosis: 14-23.
33. Kaptoge S, Armbrecht G, Felsenberg D, Lunt M, W O’Neill T, Silman AJ, and Reeve J (2004). When Should the Doc-tor Order a Spine X-Ray? Identifying Vertebral Fractures for Osteoporosis Care: Results From the European Prospective Osteoporosis Study (EPOS). JBMR, 19(12): 1982-93.
34. Cooper C, O’Neill T, Silman A (1993). The epidemiology of vertebral fractures. Bone, 14: S89-97.
35. O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996). The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. JBMR, 11: 1010-18.
36. Horowitz MC (1993). Cytokines and estrogen in bone: anti-osteoporotic effects. Science, 260: 626-27.
37. Zheng SX, Vrindts Y, Lopez M, De Groote D, Zangerle PF,Colette J, et al. (1997). Increase in cytokine production by stimu-lated whole blood cells in postmeno-pausal osteoporosis. Maturitas, 26: 63-71.
38. Einhorn TA, Majeska RJ, Rush EB, Levine PM, Horowitz MC (1995). The expression of cytokine activity by fracture cal-lus. JBMR, 10(8): 1272-81.
39. Kon T, Cho T, Aizawa T, Yamazaki M, Nooh N, Graves D, Gerstenfeld LC, Einhorn TA (2001). Expression of osteoprotegerin, receptor of activator of NF-kB ligand and related proinflammatory cytokines during fracture healing. JBMR, 16(6): 1004-14.
40. Flick LM, Weaver JM, Ulrich-Vinther M, Abuzzahab F, Zhang X, et al. (2003). Effects of receptor activator of NFkB (RANK) signaling blockade on fracture healing. J Orthop Res, 21: 676-84.
41. Lehmann W, Edgar CM, Wang K, Cho TJ, Barnes GL, Kakar S, et al. (2005). Tumor necrosis factor alpha coordinately regu-lates the expression of specific matrix metalloproteinases and angiogenic factors during fracture healing. Bone, 36: 300-10.
42. Kloen P, Di Paola M, Borens O, Richmond J, Perino G, Helfet DL,Goumans MJ (2003). BMP signaling components are expressed in human fracture callus. Bone, 33: 362–71.
43. Street J, Bao M, deGuzman L, Bunting S, Peale Jr FV, Ferrara N, et al. (2002). Vascular endothelial growth factor stimulates bone repair by promoting angioge-nesis and bone turnover. PNAS, 99(15): 9656-61.
44. Cho TJ, Gerstenfeld LC, Einhorn TA (2002). Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. JBMR, 17: 513-20.
45. Yang Xu, Ricciardi BF, Hernandez-Soria A, Shi Y, Camacho NP, Bostrom MPG (2007). Callus mineralization and matu-ration are delayed during fracturehealing in interleukin-6 knockout mice. Bone, 41: 928-36
46. Strecker W, Gebhard F, Rager J, Bruckner UB, Steinbach G, Kinzl L (1999). Early biochemical characterization of soft-tissue trauma and fracture trauma. J Trauma, 47(2): 358-64.
47. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y (1999). Immunological characterization of circulating osteoprotegerin/ osteoclastogenesis inhibitory factor: increased serum concentrations in post-menopausal women with osteoporosis. JBMR, 14: 518-27.
48. Khosla S, Arrighi HM, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL (2002). Correlates of osteo-protegerin levels in women and men. Os-teoporos Int, 13: 394-99.
49. Szulc P, Hofbauer LC, Heufelder AE, et al. (2001). Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. JCEM, 86: 3162-65.
50. Oh ES, Rhee EJ, Oh KW, Lee WYb, Baek KH,Yoon KH, Kang MI, Yun EJ, Park CY, Choi M G, YooH J, Park SW (2005). Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women. Metabolism Clinical and Experimental, 54: 49-54
51. Schoppet M, Preissner KT, Hofbauer LC (2002). RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. ATVB, 22: 549-53.
52. Khosla S (2001). Minireview: the OPG/ RANKL/RANK system. Endocrinology, 142: 5050-55.
53. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS (2003). Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum, 48: 2042-51.
54. Bu R, McKeon RM, Cao L, Blair HC (2001). Osteoprotegerin (OPG) binds TNF family proteins including TNF and protects os-teoblasts from TNF induced apoptosis: a complementary function in addition to effects of OPG on osteoclast differentiation via RANKL. JBMR, 16(1): S169.
55. Holt MI, Baattrup A, Eriksen EF (2001). Expression of osteoclast differentiating factor (ODF, RANKL) and osteprotegerin (OPG) in human bone: role of the bone remod-eling compartment in the coupling between resorption and formation. JBMR, 16(1): S364.
56. Fahrleitner A, Prenner G, Leb G, Tscheli-essnigg KH, Piswanger-So¨lkner C, Ob-ermayer-Pietsch B, Portugaller HR, Be-rghold A, Dobnig H (2003). Serum os-teoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone, 32: 96-106
57. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Hol-loway DL, Zhang C, Peterson MC, Bek-ker PJ (2006). AMG 162 Bone Loss Study Group: denosumab in postmenopausal women with low bone mineral density. NEJM, 354: 860-63.